Pharmaceutical value under uncertainty: a theory of reproducible therapeutic surplus
Frontiers in Pharmacology · 05.11.2026 · 17
DOI: 10.3389/fphar.2026.2041618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.11.2026. Verfasst von Guido Attilio Condorelli und 3 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pharmacoeconomics has achieved considerable influence by providing formal tools for comparing pharmaceutical interventions in terms of costs and consequences. Its most established instruments, especially cost-effectiveness analysis and related evaluative frameworks, have supplied health systems with a disciplined language for priority setting, reimbursement appraisal and resource allocation (1,2). This contribution is substantial and should not be understated. Yet the intellectual success of conventional pharmacoeconomics has also encouraged a narrowing of its theoretical horizon. In much of its dominant form, pharmaceutical value is treated as if it could be adequately represented through a relatively static relation between present expenditure and measurable health gain.That reduction has analytical advantages, but it also entails a substantial loss of theoretical depth. Pharmaceutical interventions do not enter empty calculative space. They are introduced into health systems characterised by imperfect information, asymmetries of institutional power, intertemporal trade-offs, administrative delay, evidential incompleteness and politically mediated thresholds of acceptability. Even where the formal apparatus of economic evaluation is technically rigorous, the broader process by which value is formed, recognised and acted upon remains only partially captured by standard efficiency metrics. In this sense, conventional pharmacoeconomics is not wrong so much as incomplete. It explains an important part of the problem, but not the full architecture within which pharmaceutical value is generated and judged. This incompleteness becomes particularly evident once one distinguishes between the evaluation of a medicine as an isolated intervention and the evaluation of a medicine as an element within a reproducing institutional system. A pharmaceutical technology may satisfy conventional criteria of efficiency while simultaneously imposing strains on future therapeutic organisation, reimbursement flexibility, supply resilience or distributive legitimacy. By the same token, a therapy that appears expensive in the short run may contribute to the strengthening of long-term therapeutic capacity by reducing downstream fragility, preserving clinical options or stabilising patterns of care. The prevailing analytical vocabulary of pharmacoeconomics has struggled to articulate these broader dynamics in a systematic way.The reduction of pharmaceutical value to static efficiency is increasingly difficult to defend. Even within mainstream health economics, important work has acknowledged that cost-effectiveness analysis, although indispensable, does not exhaust the evaluative terrain of health policy (3,4). Health technology assessment bodies routinely consider matters that exceed the simple ratio between cost and effect, including severity, uncertainty, unmet need, feasibility of implementation, budgetary sustainability and wider social or institutional concerns. The real decision space is therefore already broader than the formal language by which it is often represented. Moreover, pharmaceutical decision-making unfolds under conditions of uncertainty that are not merely technical but structural. Evidence at the point of pricing and reimbursement is frequently incomplete, immature or contingent upon evolving real-world use. Uncertainty concerns not only parameter values in a model, but the stability of treatment effects over time, the generalisability of trial results, the behaviour of providers and patients, the durability of supply, and the institutional willingness to sustain funding commitments. For this reason, uncertainty is not an external nuisance appended to otherwise stable valuations; it is internal to the constitution of value itself (5)(6)(7).A further limitation of static efficiency lies in its weak grasp of temporality. Static assessment is primarily concerned with whether a given intervention appears worthwhile at the moment of appraisal. Yet pharmaceutical systems are not static allocation devices. They are historically layered, institutionally constrained and continuously reproducing arrangements that must preserve future therapeutic possibility while managing present scarcity. Recent work on dynamic efficiency has sharpened this point by showing that short-run allocative logic may diverge from the long-run conditions required to sustain socially valuable innovation and therapeutic progress (8). However, the same insight extends beyond innovation incentives narrowly understood. It also applies to the capacity of health systems to preserve therapeutic productivity, absorptive resilience and equitable access across time.If value is understood only as current efficiency, then what disappears from view is the question of whether present pharmaceutical choices support or erode the future conditions of care. A health system may approve interventions that are efficient within modelled boundaries while becoming more brittle in organisational, distributive or fiscal terms. Conversely, it may reject or delay interventions whose deeper contribution lies in their ability to stabilise therapeutic trajectories under uncertainty. Static efficiency is therefore a necessary but insufficient criterion. It captures a slice of value, but not its full temporal and institutional structure.This article advances a theoretical framework designed to address that gap. Its central claim is that pharmaceutical value should be interpreted not only in relation to immediate health gain and present cost, but also in relation to the capacity of a pharmaceutical intervention to preserve, reproduce or enlarge the future therapeutic productivity of the health system. To conceptualise this, the article introduces the notion of reproducible therapeutic surplus. The concept refers to the surplus generated when a pharmaceutical intervention yields present therapeutic benefit while also reinforcing the institutional and material conditions under which future therapeutic benefit can continue to be produced.The contribution is twofold. First, the article offers a critique of standard pharmacoeconomic reasoning by showing that its dominant evaluative categories remain theoretically under-specified in the face of uncertainty, institutional mediation and intertemporal system effects. Secondly, it proposes an alternative conceptual lens through which pharmaceutical value may be understood as an institutionally mediated and temporally extended phenomenon rather than as a merely static efficiency relation. This shift does not reject economic evaluation. Rather, it seeks to relocate economic evaluation within a richer theory of how therapeutic value is socially organised, politically filtered and historically reproduced.The broader ambition of the article is to strengthen the theoretical foundations of pharmacoeconomics by bringing it into more explicit dialogue with institutional and evolutionary modes of reasoning. If pharmaceutical systems are judged only by what they optimise in the present, they risk undermining the very conditions that make durable therapeutic progress possible. A more adequate theory must therefore ask not only whether a medicine is efficient now, but whether it contributes to the continuing reproducibility of therapeutic capacity under conditions of uncertainty, scarcity and institutional constraint. It is from this problem that the present argument begins. Cost-effectiveness analysis has become the most recognisable analytical language of modern pharmacoeconomics because it offers a formally disciplined way to compare therapeutic alternatives under resource constraints. Its appeal lies in its apparent neutrality: costs are related to outcomes, alternatives are ranked, and decision-makers are given a structured basis for reimbursement and prioritisation. In this respect, the centrality of cost-effectiveness is understandable and, within limits, justified (1,2).Yet the authority of cost-effectiveness should not be confused with theoretical completeness. Costeffectiveness analysis does not reveal value in its entirety; it isolates one dimension of it under a specific set of assumptions. It asks whether a pharmaceutical intervention generates sufficient incremental benefit relative to incremental cost, but it does not by itself determine whether that intervention is institutionally absorbable, distributively tolerable, politically sustainable, or strategically coherent with the longer-term reproduction of therapeutic capacity. Even when modelled with technical sophistication, the framework remains a partial representation of a broader evaluative field. This limitation is not merely philosophical. Real reimbursement systems do not rely on costeffectiveness alone. They operate through decision architectures in which relative effectiveness, unmet need, severity, budget impact, social value judgements, procedural conventions and institutional feasibility enter, explicitly or implicitly, into final determinations (3,4,9). The practical importance of cost-effectiveness therefore coexists with the fact that no mature decision system treats it as a self-sufficient criterion. The formal metric remains central, but the judgement of value exceeds the metric.The point, then, is not that cost-effectiveness analysis should be displaced, but that it should be resituated. As long as pharmacoeconomics treats it as the definitive expression of pharmaceutical value, it will continue to under-theorise the gap between evaluative model and institutional decision. That gap is not accidental. It reflects the fact that pharmaceutical value is shaped by a plurality of considerations that cannot be reduced to a single efficiency ratio without conceptual loss.The limitations of standard pharmacoeconomic reasoning become sharper under conditions of uncertainty. In principle, economic evaluation already recognises uncertainty and has developed increasingly refined methods for handling it, including deterministic sensitivity analysis, probabilistic analysis, scenario exploration and value-of-information approaches (5,10). These tools are indispensable, but they often remain most effective where uncertainty is quantifiable, parameterised and amenable to formal modelling.Pharmaceutical decision-making, however, frequently confronts forms of uncertainty that are only partially reducible to model inputs. At the point of appraisal, evidence may be immature, based on surrogate endpoints, derived from selected populations, or dependent on extrapolations whose plausibility cannot be fully validated in advance. Uncertainty may concern not only the magnitude of effect, but the very stability of the evidential basis on which the intervention has been valued. In such contexts, the issue is no longer simply whether a model is robust to changing parameters. It is whether the underlying object of judgement is sufficiently knowable for model-based efficiency estimates to bear the weight placed upon them (6,7). This is why uncertainty in pharmaceutical policy is not merely technical; it is also behavioural and institutional. Decision-makers differ in their tolerance for evidential fragility, and that tolerance is shaped by context, disease area, perceived unmet need and the moral weight attached to delaying access. Qualitative work on reimbursement committees has shown that uncertainty is not processed in a uniform or mechanical manner, but interpreted through heterogeneous judgements about risk, harm, necessity and acceptable compromise (11). What enters the decision is therefore not uncertainty alone, but uncertainty filtered through institutional judgement.Once this is recognised, the insufficiency of standard pharmacoeconomic reasoning becomes more evident. A framework centred mainly on expected cost and expected effect risks presenting value as more determinate than it truly is. It may also obscure the asymmetry between present modelled benefit and future irreversible commitment. Reimbursement decisions are not abstract exercises in statistical expectation. They are binding institutional acts taken under incomplete knowledge, often with consequences that are fiscally persistent, politically visible and difficult to reverse. A theory of pharmaceutical value that does not internalise this deeper form of uncertainty remains analytically underdeveloped.Pharmaceutical value is never assessed in a vacuum. It is mediated by institutions that define admissible evidence, sequence appraisal steps, assign deliberative authority, structure negotiation, and translate evaluative conclusions into funding outcomes. For this reason, the same pharmaceutical technology can generate different reimbursement trajectories across jurisdictions not only because of different prices or epidemiological profiles, but because the institutional forms of assessment themselves differ in aims, procedures and governing conventions (12,13).Institutional mediation matters because assessment is not a passive act of observation. It is an active process of selection and valuation. Institutions decide which uncertainties are tolerable, which comparators are legitimate, which benefits are decision-relevant and which trade-offs can be justified publicly. In doing so, they do not simply register pharmaceutical value; they participate in its construction. This is particularly evident where pricing and reimbursement are closely connected. In such settings, the final value assigned to a medicine emerges from the interaction between evidence review, appraisal culture, negotiation practices and budgetary doctrine rather than from any single technical estimate alone. Evidence from the Italian context, for example, suggests that economic evaluation does influence pricing decisions, but within a framework in which broader value criteria remain only partly formalised and negotiation retains a decisive role (14).The implication is substantial. If value is institutionally mediated, then pharmacoeconomics cannot remain satisfied with a model of reasoning in which institutions merely apply external evidence to pre-given decisions. Institutions shape the meaning, admissibility and practical force of that evidence. They also determine whether pharmaceutical adoption strengthens or destabilises the broader organisation of care. What appears as a favourable intervention at the level of isolated model comparison may prove less valuable once examined through the institutional conditions required for access, continuity, financing and long-term therapeutic integration.Standard pharmacoeconomic reasoning has often treated these institutional processes as contextual complications surrounding the real analytical core. The present argument takes the opposite view. Institutional mediation is not peripheral to pharmaceutical value; it is constitutive of it. Any theory that neglects this will struggle to explain why apparently efficient technologies are contested, delayed, re-priced, restricted or unevenly adopted across systems that are, in formal terms, evaluating the same evidence. The limits of conventional pharmacoeconomics therefore lie not only in its treatment of efficiency and uncertainty, but also in its insufficient account of the institutional structures through which value is made operational. Once pharmaceutical reimbursement is examined as an institutional process rather than as a merely technical application of economic evidence, it becomes apparent that value is shaped by behaviour, convention and precaution as much as by formal estimation. Reimbursement bodies do not simply infer decisions from incremental cost-effectiveness ratios. They deliberate under evidential incompleteness, interpret the moral and political implications of delay, weigh the reversibility of error, and embed economic outputs within broader judgements concerning severity, unmet need, affordability and legitimacy (9,11,15). Pharmaceutical value, in practice, is therefore not merely calculated. It is institutionally interpreted.This becomes especially clear when high-cost medicines enter the system with immature evidence. Under such conditions, conventional ex ante appraisal often proves insufficient to support either confident acceptance or straightforward rejection. Managed entry agreements emerged precisely within this space of institutional tension. Their function is not simply to modify price, but to construct a provisional governance mechanism through which uncertainty, access pressure and budgetary exposure can be held together long enough for a politically and administratively workable decision to be made (16,17). In this sense, they reveal something fundamental about pharmaceutical value: under real-world conditions, value is frequently treated as contingent and administrable rather than as a stable property fully knowable at the moment of appraisal.Comparative evidence strengthens this point. The use of managed entry agreements across Europe, including Central and Eastern European settings, demonstrates that such instruments have become recurrent policy responses where evidence is incomplete, prices are high and institutional heterogeneity is substantial (18). Their diffusion therefore cannot be explained solely by technical advances in pricing or reimbursement design. It also reflects a wider transformation in the conventions of public decision-making, whereby uncertainty is no longer treated as an exceptional nuisance but as a normal condition of pharmaceutical appraisal that must itself be governed.The oncology field illustrates this particularly well. Cancer medicines often combine high prices, multiple indications, accelerated evidential trajectories and intense access pressure. In such settings, managed entry agreements have not merely functioned as supplementary financial tools; they have become instruments through which the conflict between rapid access and incomplete knowledge is displaced from the formal appraisal stage into downstream governance and negotiation (19). This may facilitate earlier reimbursement, but it may also generate opacity, administrative complexity and shifting evidential burdens. Ex-post evidence suggests that managed entry agreements can improve the likelihood of reimbursement and thus availability, while at the same time lengthening the path to final funding decisions and leaving unresolved whether the interventions approved in this way create superior long-run value for patients and health systems (20). Their significance is therefore doubleedged: they show the practical adaptability of reimbursement systems, but also expose the inability of static valuation to settle the problem decisively.This broader pattern helps explain why apparently similar technologies may generate different funding outcomes across jurisdictions. Divergence in HTA recommendations does not arise only from differences in clinical evidence or price. It is also driven by differences in appraisal culture, institutional thresholds, deliberative conventions and the behavioural tolerance of uncertainty (21,22). Pharmaceutical value is thus mediated through institutional repertoires of judgement. What counts as an acceptable risk, a tolerable compromise or a sufficient degree of evidence is never purely technical. It is embedded in the behavioural grammar of the decision system itself.A broader theory of pharmaceutical value requires a corresponding shift in the unit of analysis. Static optimisation treats the medicine as an isolated object of appraisal. A systemic perspective begins from the recognition that medicines enter institutional environments that must continuously reproduce their own capacity to generate therapeutic benefit. What is at stake is not only whether a pharmaceutical intervention appears worthwhile at a given moment, but whether the terms of its adoption preserve or undermine the future organisation of therapy.The concept of pharmaceutical
Zitieren
APA
Condorelli, G. A., Capri, S., Solà‐Morales, O., & Drago, F. (2026). Pharmaceutical value under uncertainty: a theory of reproducible therapeutic surplus. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2041618
Vancouver
Condorelli GA, Capri S, Solà‐Morales O, Drago F. Pharmaceutical value under uncertainty: a theory of reproducible therapeutic surplus. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2041618
BibTeX
@article{Condorelli2026,
author = {Condorelli, Guido Attilio and Capri, Stefano and Solà‐Morales, Oriol and Drago, Filippo},
title = {Pharmaceutical value under uncertainty: a theory of reproducible therapeutic surplus},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2041618}
}
EUVIMED